Product Description
The research-grade biosimilar is an antibody-drug conjugate that targets TROP-2 that is expressed on cancer cells. The original conjugate consists of an anti-TROP2 humanized monoclonal antibody (RS7-3G11) that is chemically linked to a cytotoxic drug SN-38 via a hydrolyzable CL2A linker. Upon internalization in the cell, the SN-38 is released from the antibody via the hydrolysis of the CL2A linker. SN-38 inhibits DNA topoisomerase I and induces DNA-damage mediated cell death. The original antibody-drug conjugate received approval from the FDA in 2020 to treat patients with metastatic triple-negative breast cancer who have received at least two prior treatment regimens
Biovision | A2175 | Anti-TROP2 (Sacituzumab Govitecan), Humanized Antibody DataSheet
Antibody Target: TROP2
Target Alternative Name: IMMU-132, hRS7-SN-38, hRS7-SN-38-ADC, hRS7-[CL-SN-38], hRS 7SN38, hRS7-SN38, IMMU 132, EGP1, GP50, M1S1, EGP-1, TACSTD2, GA7331, GA733-1
Tag Line: The biosimilar is an antibody-drug conjugate that targets cancer cells expressing TROP-2 and induces cell death via DNA damage. The original antibody-drug conjugate is approved to treat metastatic breast cancer
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human TROP2
Accession #: DB12893
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE